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Abstract
Background: It is estimated that 22,800 children were living with an Acquired Brain Injury (ABI) (0.6% of children
aged under 15 years) in Australia during 2003. Many children after a traumatic brain injury will experience
difficulties with attention and concentration; a condition termed secondary Attention Deficit-Hyperactivity Disorder.
There is conflicting evidence on whether treatment with stimulant therapy with medications such as
methylphenidate or dexamphetamine will improve the attention and behavior of children with this condition.
Methods/Design: Single patient trials (n-of-1s or SPTs) evaluate the effect of titrated doses of psychostimulants
methylphenidate or dexamphetamine compared to placebo on attention and behavior, in children with TBI and
secondary ADHD. The aggregation of multiple SPTs will produce a population estimate of the benefit. Forty-two
children will be registered into the trial through rehabilitation services at three large children’s hospitals in Australia.
Patients will complete up to 3 cycles of treatment. Each cycle is 2 weeks long comprising seven days each of
treatment and placebo, with the first two days of each cycle considered a washout period and the data not
analysed. The order of treatment and placebo is randomly allocated for each cycle. The Conners’ Parent Rating
Scales long forms will be employed to measure change in attention-deficit/hyperactivity and related problems of
the child, and the primary outcome measure is the Conners’ Global Index Parent Version. Secondary outcomes
include the teacher and child (if aged > 12 years) Conners’ Rating Scales, the Behaviour Rating Inventory of
Executive Function among other measures. This study will provide high-level evidence using a novel
methodological approach to inform clinicians about the most appropriate treatment for individual children.
Through aggregation of individual trials, a population estimate of treatment effect will be provided to guide clinical
practice in the treatment of children with secondary ADHD after a traumatic brain injury.
Discussion: This study employs an innovative methodological approach on the effectiveness of CNS stimulants for
secondary ADHD from a brain injury. The findings will both guide clinicians on treatment recommendations, and
inform the concept and acceptance of SPTs in paediatric research.
Trial registration: Australian New Zealand Clinical Trials Registry. ACTRN12609000873224
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Background
During 2003, one in forty-five (432,700) people in
Australia experienced an acquired brain injury (ABI)
causing a disability with activity limitations or partici-
pation restrictions [1]. It is estimated that 22,800 chil-
dren were living with an ABI (0.6% of children aged
under 15 years) in Australia during 2003 [2].
Consequences for children with TBI are difficulties
with attention, concentration and self-regulation [3,4].
Up to 4 years after TBI, a fifth to one-half of the chil-
dren will have a clinically significant attention disorder
[5]. TBI derived attention disorders are comparable to
developmental forms of Attention Deficit Hyperactivity
Disorder (primary ADHD) and have been termed ‘Secon-
dary ADHD’ [6]. Symptoms of secondary ADHD include
clinically significant difficulties with attention, concentra-
tion, impulse control and hyperactivity, although TBI asso-
ciated hyperactivity may be less severe than with primary
ADHD [6].
Central Nervous System Stimulants are often a first-
line treatment option in the treatment of primary
ADHD [7], but there is a scarcity of well-designed stud-
ies on the efficacy of stimulant therapy for reducing the
attention, concentration and impulsivity symptoms of
secondary ADHD in paediatric populations. One double-
blind, placebo-controlled, cross-over trial evaluated the ef-
ficacy of methylphenidate hydrochloride (MPH) (up to 10
mg per day over four days) on attention, memory, behav-
iour, processing speed and psychomotor skills of children
(n=10, aged 5–16 years) who had experienced a TBI. The
injury ranged from mild to severe and participants were
clinically consistent with an ADHD diagnosis. No signifi-
cant change occurred in any of the measures [8]. In con-
trast, Mahalick et al. describe a double-blind, placebo-
controlled cross-over trial in children (n=14, aged 5–14
years) with a range of head injury severity who had ac-
quired attentional disorders secondary to injury, evaluat-
ing MPH at a dose of 0.3 mg/kg twice daily over 14 days.
A significant treatment effect was found on attention and
concentration (p<0.05) [9]. Given the contradictory find-
ings in the literature, and the potential benefits to children
if effective, this protocol will describe a study that identi-
fies both the children who will benefit and those who will
not on a case-by-case basis and provides a population esti-
mate of treatment effect using an aggregated n-of-1 trial
design.
N-of-1 trials
N-of-1 trials are multiple-cycle, double blind, placebo-
controlled crossover trials using standardized measures
of effect. The randomisation order is independently gen-
erated for each patient and they provide the strongest
evidence about treatment efficacy in an individual
patient [10]. This may be particularly important in the
population of children with ABI, as some individuals are
more likely to respond than others [9,11]. At trial’s end
for the individual, the randomisation order is revealed
and the treatment effect for the specific individual is de-
termined based on response while on treatment versus
control. By aggregating the results of all of the n-of-1 tri-
als testing a particular drug, a treatment effect can be
established for the patient population [12-14].
Methods/Design
Study aims
This study will test the efficacy of stimulant therapy with
MPH or dexamphetamine (DEX) to improve attention
and concentration, and executive dysfunction (including
disorders of behavioural and emotional regulation) in
children with traumatic brain injury compared to placebo
by providing both a population and an individual estimate
of treatment effect. A secondary aim is to evaluate the
feasibility of n-of-1 trials as a means of conducting clinical
trials within paediatric rehabilitation.
Study design
A series of randomised, double-blind, placebo-controlled,
single patient (n-of-1) trials conducted in three centres.
Each participant will undergo three cycles, each of 2
treatment periods. The duration of each treatment period
will be 1 week, making a total of 6 weeks per participant
to complete the full trial. The first 2 days of each treat-
ment period will not be used to assess efficacy, to allow
for washout of active medications (half-lives: MPH 4
hours; DEX 6–8 hours). In each cycle, the drugs (stimu-
lant or placebo) are randomly allocated to the participat-
ing child with both investigators and the participant
blinded (see Figure 1). At the end of the trial, the order
of medications is unmasked, and compared with the par-
ent and teachers’ observations of the child’s behaviour.
Repeated outcomes in the same direction favouring the
treatment are reported in terms of a probability that the
finding is correct. Multiple n-of-1 trials will be aggre-
gated to produce a population estimate of the effect of
stimulants.
Study population and recruitment
Children who are outpatients will be recruited from
three participating sites, the Brain Injury Service at the
children's hospital at Westmead, the Queensland Paedi-
atric Rehabilitation Service and Sydney Children’s Hos-
pital. Participants will be invited to participate if they are
aged between 6 and 16 years old, have a clinical diagno-
sis of moderate to severe brain injury, and are at least 12
months post-injury. Severity of brain injury is based on
duration of loss of consciousness, initial Glasgow Coma
Scale Score (GCS) at presentation to the treating hos-
pital and duration of post-traumatic amnesia (PTA).
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Moderate TBI is defined as a loss of consciousness for
30 to 60 minutes, or GCS 9–12, or PTA from 1 day to 1
week; and severe TBI as loss of consciousness > 60 mi-
nutes, or GCS < 9, or PTA > 1 week. They must also
have a clinically diagnosed and significant attention/con-
centration disorder or executive dysfunction (including
behavioural or emotional regulation disorders) that may
respond to stimulants. The participant must have at least
two people (parent or other person, teacher) who can
consistently monitor the child’s symptoms to allow data
collection. Children are excluded if they have any of the
following clinical conditions: uncontrolled seizure dis-
order, moderate to severe hypertension, clinically signifi-
cant anxiety, motor tics, Tourette syndrome, suspected
or proven cardiac conduction problems, idiosyncratic re-
action to sympathomimetic amines, or history of drug
abuse (including high caffeine beverages and appetite
suppressants). Other criteria for exclusion are if the par-
ent is unable to fill out forms in English or the child’s
school is unwilling to participate.
Primary outcomes
The child (if aged > 12 years), parent and the child’s
teacher will each complete a weekly diary containing the
primary and secondary outcome measures. The Conners’
Parent Rating Scales long forms will be employed to
measure change in attention-deficit/hyperactivity and re-
lated problems of the child and the primary outcome
measure is the Conners’ Global Index Parent Version
(CGI-P) [15]. Conners’ is a widely used measure of
attention-deficit/hyperactivity and related problems for
children aged 8 to 18 years. Subscales include inat-
tention, hyperactivity/impulsivity, learning, executive
functioning, aggression and peer relations, as well as
subscales mapping onto DSM-IV criteria [16] for ADHD
(inattentive), ADHD (Hyperactive-impulsive), ADHD
combined, Conduct Disorder, and Oppositional-Defiant
Disorder. The CGI-P is a brief measure of general psy-
chopathology comprised of 10 items embedded within
the long form rating scales. It is a measure of the sever-
ity of ADHD symptoms including hyperactivity and at-
tentional deficits. Ratings are on a 4-point Likert scale,
and are converted into normalised scores, if normative
data is available.
Secondary outcomes
Secondary measures include the teacher and child (if aged
older than 12 years) Conners’ 3 long form rating scales for
teacher or child [15]. Other secondary measures include
the Behaviour Rating Inventory of Executive Function
(BRIEF) questionnaire to be completed each by the parent
and teacher [17]. This is a measure of executive function-
ing in the home and school environments. Additional data
include diagnosing the presence or absence of ADHD
using DSM-IV criteria [16], demographics, type and du-
ration of symptoms due to brain injury, date of injury, and
history of previous stimulant therapy.
Randomisation
The trial is composed of 3 cycles, each with 2 treatment
periods of a week, giving a total duration of 6 weeks. A
computer generated randomisation schedule created by
the study statistician and held by the site pharmacies
(and not accessible to investigators) will predetermine
the order of medication (stimulant (MPH or DEX) or
placebo) in each cycle.
Randomisation
Days1-6
Days 7-12
Days 13-18
Informed Consent
Baseline Assessment 
Eligibility Confirmation
Participant Assessment 
Participant Assessment 
Participant Assessment 
Figure 1 Example of n-of-1 Design Schema1.
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Safety reviews
At each contact with the researcher and via the parent
diary, adverse events will be recorded. Parents will be
contacted weekly (or more frequently if there are any
concerns) to ensure diary completion and to ask about
any adverse events.
Seriousness, causality, severity and expectedness of ad-
verse events will be evaluated. Cases that are considered
serious, possibly, probably or definitely related to the
drug and are unexpected are to be unblinded. Any
study-related problem posing risk of harm to partici-
pants and any type of serious adverse event will be
reported to the institutional ethics committee and to the
Data and Safety Monitoring Board (DSMB).
Treatment, concomitant medications and compliance
The study drug to be tested is Methylphenidate or
Dexamphetamine versus Placebo. The dose to be trialled
will be individually titrated to each child as per accepted
clinical practice, prior to randomisation (see below).
Participants will be randomly assigned to each of the
following medications in each of the three cycles.
1. Active medicine
a. MPH - maximum dose 0.3 mg/kg
b. MPH – long acting tablets (on pre-trial dose) OR
c. DEX - maximum dose 0.15 mg/kg/DOSE
2. Placebo - visually matched capsule at the same dose
as test medicine.
One 5 mg tablet dexamphetamine and one 10 mg tab-
let methylphenidate are equipotent. The pharmacist will
purchase the trial medication and placebo, organize en-
capsulation, and package trial medications at the titrated
dose in Webster packs according to the randomisation
schedule. The pharmacy will produce 3 × 1 week’s sup-
ply of active drug and 3 × 1 week’s supply of placebo, in
capsule form. Compliance will be determined by capsule
count at the end of the study.
Pre-trial dose titration of study medication
There is variation in required dose amongst children
under treatment. If the child is not already stabilised on
methylphenidate or dexamphetamine, prior to the trial
commencement he/she will be stabilised on an appropri-
ate individualised dose. They will be stable on this dose
for approximately two weeks prior to commencement of
the trial, unless already on stimulant medication prior to
recruitment. The appropriate dose is one that provides a
clinical improvement in target behaviours, and is well-
tolerated with minimal side-effects, up to the maximal
recommended dose. If unacceptable side effects occur
while taking one of the stimulants, consent will be
sought to enrol into the trial using the other stimulant.
Children who were prescribed long acting methylphen-
idate before the trial, and the treating clinician’s assess-
ment is they were likely to benefit from long-acting
MPH, will be invited to participate in the trial with long-
acting MPH as the trial test drug, on a case-by case
basis. Others will be offered short-acting MPH or DEX.
Post-trial treatment for individual patients
Once the analysis has been completed for a specific
child, a report detailing the findings, adverse events dur-
ing placebo and treatment, and recommendations to
continue or stop treatment with trial medication is sent
to the child’s paediatrician. An appointment is made for
the child to discuss the results with their doctor and to
make a decision regarding further treatment with MPH
or DEX. Clinicians who recruit participants will most
likely also be responsible for receiving the post-
treatment report. This potentially may unblind the clin-
ician about the possible effectiveness of the test drug
after viewing a number of post-treatment reports. How-
ever, any selection bias is minimised in the study design
as all participants randomly receive both the treatment
and placebo therapies. Observer bias is minimised as
data is collected from the parent, teacher (and child) in-
dependent of the clinician.
Statistical considerations
Sample size and feasibility
The Conners’ Parent Rating Scales (long form) will be
employed to measure change in attention-deficit/hyper-
activity and related problems of the child with the total
CGI-P score as the primary endpoint in this study to cal-
culate the sample size. Currently, there are no validated
scales that measure hyperactivity in children with ac-
quired brain injury; the Conners’ Scales are designed for
children without brain injury, and are used in ADHD
diagnosis. As normative scales for the Conners’ Rating
Scale have yet to be created for the study population, a
pilot study employing the same methodology (n=10) was
undertaken to ascertain completion rates and parameter
estimates. In this pilot, 80% completed cycle I, 60% com-
pleted cycles I and II, 50% completed cycles I, II and III,
the mean treatment difference equalled 2.4 (SD 6.2), and
the within-patient serial correlation between repeated
measures was 0.24. Applying these completion rates and
estimates, assuming no period effect or treatment×time
interaction, the study statistician (PS) designed a
computer-based simulation model in Stata version 12.0
statistical software (StataCorp, College Station, Tex,
USA) to derive the required sample size. Using simula-
tions of size N=10,000, and defining statistical signifi-
cance as α=5% (2-sided), 70 patients need to be enrolled
to detect a mean treatment mean difference in the total
CGI-P score of 2.0 with 80% power. Of the 70 patients,
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it is expected that 35 patients will complete cycles I, II
and III, 7 patients will complete cycles I and I, 14 pa-
tients will complete cycle I, , and 14 patients are not
expected to complete any cycles. In a similar single cycle
trial of stimulants in ABI, Bakker and Waugh [18]
recruited 25 participants from 3 sites over one year, with
1500 children (aged 6 to 12 years) on the combined
brain injury database of 2 of these sites. We estimate it
is feasible to recruit 70 participants over 3 sites as we
will recruit children over a wider age range and a re-
cruitment period of two years.
Statistical analysis
Measures on the Rating Scales will be compared within
pairs of treatment periods for each trial. We will calcu-
late adjusted mean differences in attention, hyperactivity
(measured on the Conners’ instrument) and other vari-
ables such as aggression, impulsivity, risk-taking be-
haviour, fatigue scores between treatments using
hierarchical Bayesian (HB) random effects models. For
details of the advantages of Bayesian approaches over
conventional frequentist statistical methods, refer to
Zucker et al. 1997, Schluter and Ware 2005, and Nikles
et al. 2011 [11-13]. In brief, the Bayesian approach
allows both individual and aggregate analyses to be sim-
ultaneously conducted even when the number of com-
pleted cycles varies between patients. The method
incorporates natural hierarchies and serial correlations
(e.g. clustering by physician, setting or location), the out-
come variables can take any parametric functional form,
and relevant information sourced from within the trial
and elsewhere can be included to produce coherent esti-
mates and confidence intervals [11-13]. Frequentist
methods offer no such guarantee [12,13]. Despite these
advantages, Bayesian approaches are not routinely
employed in medical research as they are often perceived
as being analytically complex and difficult to conduct.
However, a cost free and easily implementable down-
loadable software programme, WinBUGS, [19] chal-
lenges this perception and will be used in this study (see:
www.mrc-bsu.cam.ac.uk/bugs/winbugs/contents.shtml).
We will assume a clinically important difference of 0.3
standard deviations for all scores. For normally distrib-
uted data, we will follow the method advocated by
Zucker and colleagues, [13] and use their standard non-
informative prior and hyperprior distributions. For
binary data, we will employ the corresponding non-
informative prior specifications and methods described
by Schluter and Ware [12]. The likelihood distributions
will be assessed for violations and data transformations
undertaken, where necessary. Also, as we are conducting
the study over multiple sites, an apposite hierarchy
structure will be introduced into all models that accom-
modates this clustering [13]. To describe participants’
overall response, three types of Bayesian results will be
presented: (i) the mean of the posterior distribution of
the mean difference between placebo and stimulant
scores, which gives the best estimate of the overall effect
size difference between treatments; (ii) the associated
95% credible region, which give intervals of uncertainty
(in this case the 2.5 and 97.5 percentile) of the posterior
distributions used in (i); and (iii) the posterior probabil-
ity of the mean difference that stimulant scores were
better than placebo scores, which describes the likeli-
hood that the patients will favour the active treatment in
future cycles [13]. A patient will be defined to be a ‘re-
sponder’ when these estimated values exceed predefined
threshold values [12].
Ethical considerations:
Ethical approval
Written approvals have been obtained from relevant
Hospital Research Ethics Committees (Royal Children’s
Hospital and Health Service District Ethics Commi-
ttee, Queensland Health; The Children’s Hospital at
Westmead HREC, Sydney) and The University of
Queensland Medical Research Ethics Committee prior
to study commencement. Approval was obtained from
Education Regulatory Authorities in Queensland and
NSW (Queensland Government Dept. of Education and
Training, Catholic Education Archdiocese of Brisbane,
NSW Government of Education and Communities,
Catholic Education Office Sydney). Informed consent is
required from the parent and teacher (and assent for
children aged >12 years). All patients receive a re-
identifiable registration number for the trial CRFs and
database.
Trial withdrawal and discontinuation of trial medication
Patients can withdraw from the trial at any time without
reason or impact on usual care. Reason for withdrawal is
recorded. Only data from completed cycles will be in-
cluded in the analysis. The trial will be stopped if DSMB
recommend stoppage due to safety concerns.
Discussion
In Australia, 0.6% of children aged under 15 years are
estimated to have experienced an ABI [2], with a fifth to
one-half of the children will have a clinically significant
attention disorder at up to 4 years after injury [5]. This
protocol describes aggregated N-of-1 trials to assess the
efficacy of psychostimulants on attention, hyperactivity
and high cerebral functions of children who have experi-
enced traumatic brain injury. Current evidence from
cross-over trials testing efficacy of psychostimulants in
this population is inconclusive. Hence, additional high-
quality evidence is required prior to recommending
treatment.
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Recruiting sufficient numbers of children who have ex-
perienced a TBI into traditional RCTs is problematic;
therefore we propose an alternative methodology while
providing high-level evidence. Due to their cross-over
design, aggregated SPTs have a smaller required sample
size than their conventional parallel arm RCT counter-
parts for equivalent levels of statistical power, and are
better at controlling for confounding [20]. As every par-
ticipant receives both the active and placebo treatments,
this makes participation more attractive than in a
conventional RCT where there is a chance of being
randomised to the placebo arm of the trial. Finally, be-
cause the same person contributes multiple data points
to both the active and placebo arms of the trial, the sam-
ple is perfectly matched.
An additional strength of this proposed study is the
pre-trial titration of psychostimulants to ensure a dose
was selected that appeared to produce positive behav-
ioural result, while being well tolerated, to allow com-
parison with placebo for each individual child. For each
child participant, at trial end a report on efficacy and ad-
verse effects is provided to the parents and the child’s
paediatrician. This is not possible in a traditional RCT.
This study will be the first to use aggregated n-of-1 trials
in a paediatric population with TBI. An important com-
ponent of the study is not only to test the efficacy of
MPH or DEX on cognitive and behavioural outcomes in
children, but to evaluate the acceptability, methodology
and analytical aspects of employing this methodology in
this patient population. This information will contribute
to proof-of-concept and ensure the acceptance of this
method as a valuable and reliable research tool especially
in drug trials where populations are difficult to recruit. As
no previous n-of-1 trials have been conducted in this area,
this reported series of trials significantly enhances paediat-
ric community rehabilitation knowledge and practice.
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